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Application of nanoparticles for the therapy of cardiac disease, such as myocardial
infarction, is an emerging field and has shown potential benefits both in vitro and in
animal models, bringing the technology closer to a potential clinical translation. As part
of the therapeutic strategies of cardiac regeneration, the direct reprogramming of
existent fibroblasts into cardiomyocytes has recently been explored by several
research groups with the aim of developing the most efficient and safe way(s) to
convert one cell type into another. Considering the poor water solubility of these
innovative pharmaceutical agents, here we developed a dual drug-loaded
functionalized AcDXSp-based nanoparticle, which promotes pH-dependently triggered
drug delivery. The functionalization of the nanosystem improved its stability and
biocompatibility, as well as provided higher specificity towards the cardiac cells. Finally,
the intriguing observation of dual therapeutic effect reinforces the suitability of this
nanosystem for pharmacologically-induced direct fibroblast reprogramming.
Overall, as a proof-of-concept and for the first time, we have described the
development of a biocompatible and functional nanodelivery system for pH-triggered
delivery of at least two poorly-water soluble small drug molecules for applications
promoting cardiac regeneration. This may be extended to other nanoparticulate-based
systems and other small drug molecules.
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Abstract: The inability of the heart to recover from an ischemic insult leads to the formation of
fibrotic scar tissue and heart failure. From the therapeutic strategies under
investigation, cardiac regeneration holds the promise of restoring the full functionality of
a damaged heart. Taking into consideration the presence of vast numbers of
fibroblasts and myofibroblasts in the injured heart, direct fibroblast reprogramming into
cardiomyocytes using small drug molecules is an attractive therapeutic option to
replenish the lost cardiomyocytes. Here, we developed a spermine-acetalated dextran-
based functional nanoparticle for pH-triggered drug delivery of two poorly-water soluble
small molecules, CHIR99021 and SB431542, both capable of increasing the efficiency
of direct reprogramming of fibroblast into cardiomyocytes. Upon functionalization with
polyethylene glycol and atrial natriuretic peptide, the biocompatibility of the
nanosystem was improved, and the cellular interactions with the cardiac non-myocytes
were specifically augmented. The dual delivery of the compounds was verified in vitro,
and the compounds exerted concomitantly anticipated biological effects by stabilizing
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β-catenin (CHIR99021) and by preventing translocation of Smad3 to the nucleus of
(myo)fibroblasts (SB431542). Our observations highlight the potential of this
nanoparticle-based system towards improved drug delivery and efficient direct
reprogramming of fibroblasts into cardiomyocyte-like cells, and thus, potential cardiac
regeneration therapy.
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The inability of the heart to recover from an ischemic insult leads to the formation of fibrotic scar tissue 
and heart failure. From the therapeutic strategies under investigation, cardiac regeneration holds the 
promise of restoring the full functionality of a damaged heart. Taking into consideration the presence of 
vast numbers of fibroblasts and myofibroblasts in the injured heart, direct fibroblast reprogramming into 
cardiomyocytes using small drug molecules is an attractive therapeutic option to replenish the lost 
cardiomyocytes. Here, we developed a spermine-acetalated dextran-based functional nanoparticle for 
pH-triggered drug delivery of two poorly-water soluble small molecules, CHIR99021 and SB431542, 
both capable of increasing the efficiency of direct reprogramming of fibroblast into cardiomyocytes. 
Upon functionalization with polyethylene glycol and atrial natriuretic peptide, the biocompatibility of 
the nanosystem was improved, and the cellular interactions with the cardiac non-myocytes were 
specifically augmented. The dual delivery of the compounds was verified in vitro, and the compounds 
exerted concomitantly anticipated biological effects by stabilizing β-catenin (CHIR99021) and by 
preventing translocation of Smad3 to the nucleus of (myo)fibroblasts (SB431542). Our observations 
highlight the potential of this nanoparticle-based system towards improved drug delivery and efficient 











































































Ischemic heart disease is the leading cause of death globally.[1] Myocardial infarction induces loss of up 
to one billion cardiomyocytes, and owing to the very limited regenerative capacity after injury,[2] the lost 
cells are replaced by a fibrotic scar tissue, leading to heart failure.[3] Although extensive efforts have been 
done to prevent, limit or treat heart failure, up to date there is still no treatment that could successfully 
restore the function of an injured heart. Gene therapy,[4] stem cell therapy with or without cardiac tissue 
engineering [5] or direct administration of proteins, pro-angiogenic cytokines [6] and transcription factors 
[7] have been reported as potential therapeutic alternatives. However, the effect of cardiac function in 
clinical trials of these interventions has been small or negligible, thus prompting to search for novel 
approaches.[8]  
Recently, small drug molecules have been reported as being of potential use for cardiac regeneration 
purposes. Key compounds are, among others,[9] transforming growth factor-β type 1 receptor kinase 
(TGF-β) inhibitors, such as SB431542,[10] and Wnt activators, like CHIR99021.[11]  TGF- signaling 
pathway is involved in many biological processes, including cell proliferation, growth, development and 
differentiation. In fibroblasts, the early activation of the TGF-β pathway stimulates pro-fibrotic signaling, 
and this over-activation attenuates reprogramming of fibroblasts into beating cardiomyocytes.[12] Thus, 
inhibition of TGF-β pathway is important for cardiac fibroblast reprogramming. SB431542 is an activin 
receptor-like kinase (ALK) inhibitor. The TGF-β canonical signaling pathway involves the 
phosphorylation of Smads by ALKs, which is necessary for subsequent translocation to the nucleus for 
initiation of downstream signaling.[13] SB431542 inhibits the phosphorylation of Smads, thereby 
hampering their translocation to the nucleus.[14] Wnt/β-catenin signaling, on the other hand, has an 
important role in morphogenesis and differentiation during vertebrate heart development, and therefore 





































































of an active Wnt ligand, β-catenin is phosphorylated with a cytoplasmic complex of proteins, involving 
also the glycogen synthase kinase 3 (GSK3), leading to β-catenin degradation. In contrast, in the activated 
Wnt state, the destruction complex is inhibited, β-catenin is stabilized in the cytoplasm and translocated 
to the nucleus for regulating expression of target genes.[16] CHIR99021 is a potent inhibitor of the GSK3 
and thereby activates β-catenin-regulated gene expression. Combinational therapies utilizing SB431542 
and CHIR99021, as well as other small molecules, are efficient in inducing direct reprogramming of 
fibroblasts into cardiomyocyte-like cells,[14, 17] or in enhancing the proliferation of human induced 
pluripotent stem cell-derived cardiomyocytes,[11b] emphasizing the potential of small-molecule 
compounds in the development of cardiac regeneration-inducing therapies.  
The application of micro- and nano-particulate systems for therapy of cardiovascular disease (CVD) is a 
relatively recent field, emerging as a promising alternative therapeutic and diagnostic approach.[18] These 
carriers serve as drug delivery vehicles for short-lived cytokines and growth factors, or/and for poorly 
water-soluble molecules, allowing a controlled release profile owing to the material features and tunable 
properties. The main advantages of the use of these drug carrier systems is the payload protection, 
prolongation and enhancement of the therapeutic effect of the intended drug compounds, along with 
lower drug administration frequency, and thus, improved patient compliance.[18-19] Examples of 
developed carriers include poly(lactide–co-glycolide) microparticles loaded with different growth factors 
alone or in combination, showing sustained release of the cargos, induction of cardiomyocyte 
proliferation and progenitor cell recruitment, attenuation of myocardial remodeling and improved cardiac 
function.[20] 
Acetalated dextran (AcDX), known for being biocompatible, biodegradable, widely available and easily 
modified,[21] is an example of a polymer with pH-dependent drug delivery properties, for protein-based 
cargos applied in CVD therapy in vivo in the form of microparticles.[22] These AcDX microparticles were 





































































infarct area.[22] Yet, the disadvantage of the above-referred drug carrier systems is the need of invasive 
intramyocardial administration. Hence, it is important to address the administration route, reduce the 
drug carrier size to below the micrometer range and functionalize the particles in order to increase the 
chances of accumulation in the injured heart upon systemic administration.[23] 
Direct reprogramming of fibroblasts has been identified as a potential therapeutic strategy for cardiac 
regeneration.[24] Hence, the aim of this study was to deliver concomitantly two poorly water-soluble 
model drugs, SB431542 and CHIR99021, which have been used in combination or with other compounds 
for direct reprogramming of fibroblasts into cardiomyocytes,[14, 17, 25] by encapsulating them inside the 
surface functionalized spermine-modified AcDX (AcDXSp) nanoparticles. We have previously 
demonstrated that atrial natriuretic peptide (ANP) functionalization of nanocarriers enhances their 
accumulation in the injured heart in vivo.[23] In addition, we have successfully applied AcDX for other 
therapeutic applications, such as cancer and immunotherapy.[26] In this study, we hypothesize that 
functionalizing the surface of AcDXSp with polyethylene glycol (PEG) can enhance the nanocarrier 
colloidal stability due to the intrinsic stealth properties of PEG,[27] while the functionalization with ANP 
can make the interaction of the nanocarrier more specific towards cardiac cells, due to the presence of 
natriuretic peptide receptors (NPR) on the cell membrane.[28] Additionally, the pH responsiveness of 
AcDXSp can provide a triggered release in the cytoplasm of cells upon internalization into the acidic 
subcellular compartments. The main goal of this study was to assess whether AcDXSp-based 







































































2. Results and Discussion 
2.1. Characterization of AcDX-based Nanosystems 
The preparation of AcDXSp nanoparticles was performed by an oil-in-water (o/w) single emulsion 
method,[29] where the hydrophobic CHIR99021 (C) and SB431542 (S; combination of C and S 
abbreviated as CS), were incorporated in the organic phase with the AcDXSp polymer. For vehicle-
loaded particles, similar conditions were used. As an aqueous phase, a solution of the stabilizer polyvinyl 
alcohol (PVA) was used, and upon the application of high energy sonication, the evaporation of the 
solvent occurred during 3 h. The drug-loaded and vehicle-loaded AcDXSp nanoparticles were further 
functionalized with PEG and ANP using crosslinking chemistry (Scheme 1), and their hydrodynamic 
diameter, polydispersity index (PdI) and zeta ()-potential were evaluated by dynamic light scattering 
(DLS) and -potential measurements (Figure 1A). 
 
Scheme 1. Illustration of the PEG and ANP stepwise functionalization of drug-loaded AcDXSp prepared 
by an o/w single emulsion method using crosslinking chemistry. Not to scale. 
 
The increase in size upon functionalization occurred similarly in both vehicle- and drug-loaded 
nanoparticles (Figure 1A), while their positive -potential values, caused by the amine groups from the 





































































COOH moieties present at the end parts of PEG (AcDXSp-P). Further functionalization with ANP 
(AcDXSp-P-ANP) maintained or slightly decreases the -potential values of the nanosystems due to the 
occupancy of ANP amine groups with the covalently attached PEG. For simplification, the loaded 
nanoparticles are abbreviated as CS@AcDXSp, CS@AcDXSp-P and CS@AcDXSp-P-ANP. The 
presence of PEG at the surface of AcDXSp functionalized nanoparticles was evaluated by attenuated 
total reflectance Fourier transform infrared (ATR−FTIR) spectroscopy (Figure 1B). The appearance of 
amide-indicative bands at 1565–1570 cm-1 (in-plane N−H bending and C−N stretching) and 1630–1640 
cm-1 (amide C=O stretching) confirmed the formation of a covalent amide bond between the AcDXSp 
and PEG, and the appearance of a shoulder at 1735 cm-1 (C=O stretching from –COOH) denotes the 
presence of free carboxyl groups. The further functionalization with ANP did not show modifications in 
the FTIR spectrum. Elemental analysis of AcDXSp-P and AcDXSp-P-ANP nanoparticles showed the 
presence of about 4.8 ± 1.7 µg of ANP in 1 mg of AcDXSp-P-ANP nanoparticles, confirming the 
successful functionalization.  
Because the in vitro studies were all performed in cell culture medium, we evaluated the colloidal 
stability of the nanosystems also in culture medium. While AcDXSp nanoparticles display a 
progressively growing hydrodynamic diameter, upon stabilization with PEG this parameter remains 
constant over time for both AcDXSp-P and AcDXSP-P-ANP (Figure 1C). This demonstrates the stealth 
properties generated by the PEG coating.[27] The PdI remained satisfactorily stable with a non-significant 
raise in the values for ANP-functionalized nanoparticles (Figure 1D). As observed and demonstrated in 
other studies, PEGylation is necessary for the stabilization of the nanoparticles and for the prolongation 
of the blood circulation time, mainly because it provides a hydrophilic coating, and at the same time its 







































































Figure 1. Physicochemical characterization of AcDXSp nanoparticles before and after surface 
functionalization. (A) Hydrodynamic diameter, PdI, and ζ-potential of AcDXSp, AcDXSp-P and 
AcDXSp-P-ANP nanoparticles, as well as the drug-loaded CS@AcDXSp, CS@AcDXSp-P and 
CS@AcDXSp-P-ANP in Milli-Q water (pH > 8). Values are represented as the mean ± standard 
deviation (s.d.) (n ≥ 3). (B) ATR−FTIR spectra of AcDXSp, AcDXSp-P and AcDXSp-P-ANP 
nanoparticles. Upon surface modification with both PEG and ANP, it was observed the appearance of 
the amide I and II bands at 1630–1640 cm−1 and 1565–1570 cm−1, respectively, indicating the presence 
of covalent amide bonds. The appearance of a band at 1716 cm−1 (carbonyl C=O stretching) in the 
AcDXSp-PEG spectrum reveals the presence of free carboxyl groups for further ANP attachment, 





































































Evaluation of the impact of cell medium on the colloidal stability of AcDXSp, AcDXSp-P and AcDXSp-
P-ANP nanoparticles upon incubation for 120 min at 37 °C. The results were calculated from the DLS 
measurement data as a function of time, and are represented as the mean ± standard deviation (s.d.) (n ≥ 
3). 
 
2.2. pH-Dependent Degradation and Drug Release 
To assess the pH-dependent degradation behavior of the polymeric matrix, we incubated each 
nanosystem in physiologically relevant buffer solutions at pH 5 and 7.4, which simulate the conditions 
inside the cellular acidic compartments [31] and the extracellular environment, respectively. Figure 2A 
shows the degradation behavior of the different nanosystems, and only mild alterations in their integrity 
were noted at pH 7.4, which are reflected in the release profile of the cargos in Figures 2B and 2D. On 
the other hand, the disintegration of the nanoparticle structure occurred much faster at pH 5, which is in 
line with a faster release of the cargos (Figures 2C and 2E). These observations are in agreement with 
the widely described pH-dependent hydrolysis rate features of the acetal groups of the acetalated 
dextran.[32] Altogether, the TEM images of the different nanosystems (Figure 2A), along with with the 
DLS data (Figure 1A), confirm the observations of minimal particle decomposition upon 
functionalization, and are in agreement with the progressive size increase observed in DLS 
measurements. 
Two reprogramming molecules, CHIR99021 and SB431542, were encapsulated into the polymeric 
AcDXSp matrix, which was further surface functionalized. The compound concentrations and molar 
ratios (approximately 1:2) were based on testing different concentrations in non-myocytes (data not 
shown). The encapsulation efficiency (EE) and loading degrees (LD) of bare and functionalized 
nanoparticles are shown in Table S1. Even though the surface modifications were performed at pH 





































































nanoparticles. A possible explanation for this leakage is that despite extensive washing, small amounts 
of drug may still remain on the surface of the nanoparticles. Moreover, the polymeric matrix might be 
saturated, possible due to the excessive amounts of cargos used to encapsulate inside the polymeric 
matrix. The same phenomenon has been described for siRNA encapsulation inside AcDXSp particles.[32c] 
As the IC50 values of the compounds are in the nanomolar range, we however anticipated (and 
subsequently showed, see below) that the LD attained was sufficient to produce biological responses.[33]  
To evaluate the pH-dependent release from the bare and functionalized drug-loaded nanoparticles, 
dissolution studies were performed at both pH 7.4 and 5 in sink conditions, and the free drugs were used 
as controls. While the free compounds demonstrated pH-dependent dissolution profiles, their release 
profiles in both conditions were similar and dictated by the degradation hydrolysis of the polymeric 
matrix towards mildly acidic conditions.[32a] As expected, the release occurred much faster at pH 5 
compared to pH 7.4 (Figure 2B–2E). The small amounts of cargos released at pH 7.4 are justifiable by 
a slight degradation of dextran at this pH resulting in release of a small percentage of the cargos, as 
previously reported.[34] After functionalization of the nanoparticles, a slightly faster drug release at pH 
7.4 can be noted than for the bare AcDXSp nanoparticles, possibly due to the more hydrophilic surface 
of the functionalized nanoparticles, which facilitated the interaction with the solvent molecules and 
released the cargos entrapped closer to the surface. In addition, the obtained degree of acetalation of 
46.1% for the AcDX molecule also influenced on the low drug release observed at pH 7.4, because the 
higher is the acetalation of AcDX, the lower is the degradation rate of the polymeric matrix at pH-values 
above 6.0.[22a] Furthermore, substantial amounts of both cargos were rapidly released within the first hour 
at pH 5. The dissolution rate of both drugs is therefore improved in mildly acidic conditions, and the 
release of both cargos is precisely triggered only upon acidic pH stimulus. These properties have 
previously been described also for other poorly water-soluble drugs.[35] Considering nanoparticles for 





































































internalization into acidic subcellular compartments in the cells of the target tissue. In addition, the 
ischemic myocardium presents inflammation and consequently changes in the interstitial pH to 6 – 6.5, 
[36] which makes this polymer a high-quality candidate for sustained drug delivery to the injured 






































































Figure 2. Degradation and drug release profiles of the AcDXSp nanoparticle preparations. (A) 
TEM images of the structural morphology of AcDXSp, AcDXSp-P and AcDXSP-P-ANP nanoparticles 
for time points 0, 2 h, 6 h and 1 day, incubated in simulated extracellular (pH 7.4) and intracellular (pH 
5) conditions. The degradation process of the AcDXSp matrix occurred faster at pH 5.0. Scale bars are 
23 nm. (B–E) The release profiles of CHIR99021 (B, C) and SB431542 (D, E) from bare CS@AcDXSp 
and functionalized CS@AcDXSp-P and CS@AcDXSp-P-ANP, evaluated at pH 7.4 and 5.0, at 37 °C. 
Data represent mean ± s.d. (n ≥ 3). 
 
2.3. Cytocompatibility and Cell–Nanoparticle Interactions 
The cytocompatibility of the nanosystems was evaluated in primary cardiac cells. Non-myocytes were 
starved with serum-free medium for 18 h prior to treatments in order to suppress extensive activation of 
the signaling routes investigated,[37] and serum-free conditions were maintained during the incubation 
with nanoparticles. Cardiac non-myocytes demonstrated a dose-dependent decrease in cell viability when 
incubated with bare vehicle-loaded and drug-loaded AcDXSp nanoparticles (Figure 3). Such 
observations were expected due to the highly cationic nature of the bare AcDXSp nanoparticles and the 
presence of the oligoamine spermine. The positively charged nanoparticle surface readily interacts with 
the negatively charged cell membrane, promoting high cell–nanoparticle interactions and internalization. 
However, this kind of behavior is also known to induce cell toxicity by causing disruption of membrane 
integrity; damage of intracellular compartments such as mitochondria and formation of 
autophagosomes.[38] PEGylation diminished the toxicity: no toxicity was observed even at the highest 
particle concentrations (250 µg/mL) with PEGylated and ANP-functionalized nanoparticles. This is due 
to the intrinsic hydrophilicity and bioinert properties of PEG.[39] We also evaluated the cytocompatibility 
of these nanosystems in cardiomyocytes (Figure S1). Cardiomyocytes were more resistant to the cationic 





































































observed for PEGylated and ANP-functionalized nanoparticles. This might be explained by the presence 
of bovine serum albumin in the cardiomyocyte culture medium, which might have interacted with the 
positively charged AcDXSp nanoparticles and hided their positive surfaces, thus preventing cell–
nanoparticle interactions. It has been extensively described that protein adsorption onto nanoparticle 
surface impacts the way the nanoparticles interact with cells.[40] Upon PEGylation, protein−nanoparticle 
interactions are reduced, which preserves their native surface and favors possible interactions, 
consequently inducing some degree of toxicity, as PEGylated and ANP-functionalized nanoparticles are 
mildly cationic. We have previously observed higher resistance of cardiomyocytes against the treatment 
with positively-charged nanoparticles than was the case with non-myocytes.[23] In summary, our 
functionalized nanosystems revealed to be more cytocompatible with non-myocytes even at high 
concentrations, while for cardiomyocytes, the lower concentrations were less toxic. 
 
Figure 3. Effects of nanoparticle preparations on the viability of cardiac non-myocytes. Cell 





































































cells after incubation for 6 h with vehicle-loaded (A) and drug-loaded (B) nanoparticles at concentrations 
of 10–250 µg/mL. A Student t-test was used for the statistical analysis. The results are presented as the 
mean ± s.d. (n ≥ 3). The levels of significance were set at probabilities of *p < 0.05, **p < 0.01, and ***p 
< 0.001, compared with the cell medium-treated control (DMEM).  
 
The role of ANP at the nanocarrier surface is to promote a more specific interaction with the cardiac 
cells, because they express all types of NPRs at the cell membrane level.[28b, 41] Therefore, we investigated 
the cellular interactions with the different nanosystems by incubating non-myocytes with 
Alexafluor488®-labelled nanoparticles during 1 h (Figure 4). Quenching of the fluorescence was done 
to analyze the extent of internalized nanoparticles. As expected, the interactions between cells and 
nanoparticles occurred quickly for all formulations due to the cationic surface properties. Even though 
the bare and PEGylated AcDXSp nanoparticles showed similar median fluorescence intensity (MFI) 
values, upon fluorescence quenching, the AcDXSp nanoparticles were internalized to a higher extent 
than the PEGylated and ANP-functionalized nanoparticles (Figures 4B and 4C). Because of the highly 
positive surface charge, AcDXSp nanoparticles interact readily and unspecifically with the cell 
membrane. This is in agreement with the cell viability results (Figure 3) and observations related with 
positive surfaces and enhanced cell interactions.[38] The presence of PEG in the nanoparticles decreased 
the positive charge, enhanced the hydrophilicity of the nanoparticle surface, and thus, to some extent 
reduced the unspecific cell interactions and cell uptake, at the same time improving the cytocompatibility. 
The cellular association showed to be significantly more prominent for the ANP-functionalized 
nanoparticles compared to the bare and PEGylated nanoparticles. This interaction was further displaced 
when free ANP was added into the culture medium, indicating that the nanoparticle functionalization 
with ANP enhanced the specificity of the cell–nanoparticle interactions. The same trend was observed 





































































(Figures 4A and 4C). This is due to the presence of NPR in the non-myocyte cell membrane, as the free 
ANP will compete with the AcDXSp-P-ANP nanoparticles to bind to the NPRs, thus displacing the 
specific cell−nanoparticle interactions, as described in our previous study.[23] Not ruling out the 
possibility of passive targeting due to the small particle size of our nanoparticles [42] and the presence of 
enhanced vascular permeability in the injured myocardium,[43] these properties could represent an 
advantage upon intravenous injection, due to an increased blood circulation and specific cell interaction 
mediated by NPRs, increasing the probability of nanoparticle accumulation in the injured myocardium 
and leading to a more directed drug delivery. 
 
Figure 4. In vitro quantitative cellular interaction studies. (A) Flow cytometry results for serum-
starved non-myocytes after 1 h incubation with Alexafluor488®-labelled nanoparticles (25 µg/mL). 
Median fluorescence intensity values of untreated cells (grey), nanoparticle-treated cells before 
quenching (pink) and after quenching (blue) the fluorescence at the cell surface. (B) Histograms of non-
quenched and (C) quenched fluorescence at the cell surface for untreated and nanoparticle-treated cells. 
Untreated (dotted line), AcDXSp nanoparticles (black), AcDXSp-P (grey), AcDXSp-P-ANP (blue) and 





































































measurement. Values represent the mean ± s.d. (n = 3). A one-way ANOVA followed by a Tukey-Kramer 
post hoc test was used for the statistical analysis. The significance levels of the differences were set at 
probabilities of ##p < 0.01 for comparison with AcDXSp-P-ANP (before fluorescence quenching) and 
§§§p < 0.001 for comparison between AcDXSp-P-ANP AcDXSp-P-ANP + free ANP (upon fluorescence 
quenching). 
 
2.4. Modulation of Wnt and TGF-β signaling pathways in cardiac fibroblasts 
In order to address the main goal of this study, the potential use of nanoparticulate systems for direct 
fibroblast reprogramming, we incubated pre-starved non-myocytes with drug-loaded AcDXSp-
functionalized nanoparticles. As controls, both vehicle-loaded nanoparticles and the free compounds 
were used. In all the conditions where the compounds were present, 1 µM of CHIR99021 and 2.1 µM of 
SB431542 were used in all the tests, correspondent to a safe dose of nanoparticles given, which was 
calculated based on the LD of the different nanoparticles. The biological effect was assessed by 
quantifying the staining intensity for -catenin and Smad3. After a 6-h incubation with nanoparticles, the 
cells were immunostained for nuclei (4',6-diamidino-2-phenylindole dihydrochloride, DAPI), -catenin 
or Smad3, and in addition, for a fibroblast marker, vimentin or α-smooth muscle actin (SMA), which 
demonstrated that the majority of cardiac non-myocytes were (myo)fibroblasts (Figures 5A and 5E). 
The quantification of Smad3 and β-catenin intensity was done using high content imaging from regions 
of interest corresponding to the nucleus and the cytoplasm (DAPI staining was used to define the nuclear 
area and a 5-pixel ring immediately outside the nucleus was considered to represent cytoplasm). The 
results are presented in Figures 5.  
The nanoparticles loaded with Wnt activator CHIR99021 enhanced β-catenin stabilization when 





































































of β-catenin in the cytoplasm, as well as in the nucleus (Figures 5B and 5C). Importantly, the effect of 
CHIR90221 on stabilization of β-catenin in the cytoplasm was significantly higher for CS@AcDXSp-P-
ANP compared with the free drug (p < 0.05), indicating improvement in the delivery of CHIR99021 by 
the ANP-functionalized nanoparticles. The nucleus to cytoplasm ratio of β-catenin did not differ 
significantly among groups, except for the CS group, in which to the cytoplasmic β-catenin appeared to 
be lower than in the drug-loaded nanoparticle groups (Figures 5C and 5D). Overall, these observations 
demonstrate the suitability of the functionalized nanoparticulate systems to deliver intracellularly the 
poorly water-soluble drug CHIR99021.  
The delivery of the TGF-β inhibitor SB431542 affected the intracellular Smad3 by preventing its 
translocation to the nucleus, while it did not seem to interfere with the amount of Smad3 already existent 
in the nucleus for the 6 h (Figure 5F). This is in agreement with the mechanism of action of the 
compound, since it prevents the phosphorylation of Smad3 by the ALK and the consequent Smad 
complex formation for nuclear translocation.[13] Although free SB431542 significantly increased the 
cytoplasmic Smad3 compared to its control (p < 0.05, CS vs. DMSO), this effect was more marked for 
the drug-loaded nanoparticles, as reflected by the statistically significant cytoplasmic increase of Smad3 
compared to all the other groups, including the CS group (Figure 5G, p < 0.05). This effect was also 







































































Figure 5. High-content cell imaging and quantification of β-catenin and Smad3 staining intensity 
and sub-cellular localization. (A) Representative images of non-myocyte cells treated with 
CS@AcDXSp-P-ANP at the concentrations of 1 µM of CHIR 99021 and 2.1 µM of SB 431542, and 





































































(α-SMA, red), with a 20 magnification objective. Scale bars are 50 µm. (B-D) Quantification of β-
catenin staining intensity: the average intensity of -catenin staining in the nucleus (B), in the cytoplasm 
(C) and the ratio of -catenin in nucleus/cytoplasm (D). (E) Representative images of non-myocyte cells 
treated with CS@AcDXSp-P-ANP at the dose of 1 µM of CHIR 99021 and 2.1 µM of SB 431542, and 
stained for nuclei (DAPI, blue), Smad3 (green) and the fibroblast marker, vimentin (red), with a 20 
magnification objective. (F–H) Quantification of Smad3 staining intensity: the average intensity of 
Smad3 staining in the nucleus (F), in the cytoplasm (G) and the ratio of Smad3 in nucleus/cytoplasm (H). 
The different treatment conditions are stated below each bar. The fluorescence intensity in the cytoplasm 
was quantified from a 5-pixel ring immediately outside the nucleus defined by DAPI staining, as 
indicated for one cell in panel A. The data was normalized to the untreated control. A one-way ANOVA 
followed by a Tukey-Kramer post hoc test was used for the statistical analysis. The significance levels 
of the differences were set at probabilities of *p < 0.05 for comparison with untreated; #p < for 
comparison between drug-loaded vs. vehicle-loaded nanoparticles; §p < 0.05 for comparison between 
DMSO and CS groups and ᴥp < 0.05 for comparison of loaded nanoparticles vs. CS group. Values 
represent the mean ± s.d. (n = 3).  
 
The use of nanoparticulate systems for drug delivery applications has shown numerous advantages in 
multidisciplinary biomedical fields. Delivery of small molecules, growth factors and nucleic acid cargos 
to the heart with the particulate systems using diverse strategies have been described.[18, 19b, 20, 22a, 23, 44] 
However, employment of particulate systems for the application of direct cardiac reprogramming is 
scarce and involves generally the delivery of microRNAs and viral vectors.[45] The use of small drug 
molecules for direct cardiac reprogramming is an emerging research field, yet efforts towards its clinical 





































































SB431542, we took the advantage of the beneficial properties of nanoparticulate systems to improve the 
delivery of these compounds with reported potential to enhance direct cardiac reprogramming, and thus, 
overcome the drawbacks of reprogramming techniques using multiple genetic factors with low 
efficiency, technical and safety issues.[4d, 12, 14, 24b, 24c, 47] Several reports on the combined application of 
CHIR99021 and SB431542 for cardiac fibroblasts reprogramming specifically justified the concomitant 
use of both the compounds in this study to be delivered simultaneously by a functional nanoparticulate 
system. In addition, this functional nanosystem could potentially be also explored for induction of 
cardiomyocyte proliferation, because the inhibition of GSK-3 (involved in degradation of -catenin) may 
induce cell proliferation and mitosis in cardiomyocytes as previously described.[48] Overall, to our 
knowledge, this is the first study demonstrating the potential delivery of key small-molecule drugs using 
targeted nanoparticulate systems for the purpose of direct reprogramming of cardiac fibroblasts into 
cardiomyocytes, and the potentialities for nanoparticulate carriers for applications in cardiac regeneration 






































































Application of nanoparticles for the therapy of cardiac disease, such as  myocardial infarction, is an 
emerging field and has shown potential benefits both in vitro and in animal models, bringing the 
technology closer to a potential clinical translation. As part of the therapeutic strategies of cardiac 
regeneration, the direct reprogramming of existent fibroblasts into cardiomyocytes has recently been 
explored by several research groups with the aim of developing the most efficient and safe way(s) to 
convert one cell type into another. Considering the poor water solubility of these innovative 
pharmaceutical agents, here we developed a dual drug-loaded functionalized AcDXSp-based 
nanoparticle, which promotes pH-dependently triggered drug delivery. The functionalization of the 
nanosystem improved its stability and biocompatibility, as well as provided higher specificity towards 
the cardiac cells. Finally, the intriguing observation of dual therapeutic effect reinforces the suitability 
of this nanosystem for pharmacologically-induced direct fibroblast reprogramming. Overall, as a proof-
of-concept and for the first time, we have described the development of a biocompatible and functional 
nanodelivery system for pH-triggered delivery of at least two poorly-water soluble small drug molecules 
for applications promoting cardiac regeneration. This may be extended to other nanoparticulate-based 
systems and other small drug molecules. 
 
4. Experimental section 
Synthesis of AcDX and Modification with Spermine. Dextran (5 g, MW 9–11 kDa; Sigma-Aldrich, USA) 
was dissolved into 20 mL of Milli-Q water. Sodium periodate (0.22 g; Sigma-Aldrich, USA) was added 
to the dextran solution and the mixture was stirred at room temperature for 5 h to yield partially oxidized 
dextran. Dialysis was used to purify the partially oxidized dextran against distilled water, using a 





































































oxidized dextran (3 g) was modified with 2-methoxypropene (10.6 mL, Sigma–Aldrich, USA) and 
pyridinium p-toluenesulfonate (46.8 mg; Sigma–Aldrich, USA) in anhydrous dimethyl sulfoxide (30 mL, 
Sigma–Aldrich, USA) during 1 hour under a N2 atmosphere to obtain the partially oxidized AcDX, as 
described elsewhere [26a, 49]. Triethylamine (TEA, 1 mL; Sigma–Aldrich, USA) was used to quench the 
reaction. The resulting product was precipitated in and centrifuged (10 min, 68320g). The pellet was 
washed twice with H2O and dried in vacuum at 40 °C during 48 h. Partially oxidized AcDX (2.0 g) was 
dissolved in 20 mL of DMSO and spermine (4.0 g, 19.8 mmol; Sigma-Aldrich, USA) was added to the 
solution and kept stirring for 24 h at 50 °C. Sodium borohydride (NaBH4, 1.0 g; Sigma-Aldrich, USA) 
was added and the reduction reaction was allowed to occur at room temperature at least for 24 h. 
Methanol (10 mL) and Milli-Q water (80 mL) were added to the flask to precipitate the polymer and to 
dissolve the excess NaBH4. The polymer was washed with Milli-Q water (5  180 mL, pH 8). Residual 
moisture was removed by lyophilization, yielding white spermine-modified AcDX (AcDXSp) 
powder.[32c] The degree of functionalization was determined by 1H NMR spectroscopy in DCl/D2O 
according to the method. 1H NMR (400 MHz, CDCl3): δ 1.40 (s, br, acetal), 3.25 (br, acetal), 3.45, 
3.50−4.10, 4.90, 5.10 (br, dextran). 
Preparation of AcDXSp Nanoparticles. AcDXSp nanoparticles were prepared by an o/w single emulsion 
method. AcDXSp polymer (6.5 mg) was dissolved in CH2Cl2 (0.125 mL). The compounds CHIR99021 
(300 µg, Tocris, UK) and SB431542 (500 µg, Sigma) were added to the AcDXSp solution. An aqueous 
solution of PVA (MW: 31000−50000 g/mol, Sigma) (0.25 mL, 2.0%, w/v) was further added, the mixture 
was mixed thoroughly and emulsified by sonication during 30 s on ice, with an output setting of 5 and a 
duty cycle of 50%, using a probe sonicator (Sonics VCX 750, USA). The resulting o/w emulsion was 
transferred immediately to another solution of PVA (0.75 mL, 0.2% w/v) and stirred for 3 h to allow 





































































pelleted by centrifugation (16100g, 5 min), washed twice with Lutrol® F127 0.5 % pH 8 (BASF) and 
once with Milli-Q. All supernatants were kept for detection of CHIR99021 and SB431542 content by 
HPLC. Vehicle-loaded nanoparticles were prepared similarly. 
Surface Modification of AcDXSp Nanoparticles. The surface of the AcDXSp nanoparticles was modified 
with PEG (CO2H-PEG-CO2H, MW: 2000 g/mol, Sigma-Aldrich, USA) and atrial natriuretic peptide 
(ANP, MW: 3080 g/mol, United BioSystems Inc, USA), following a protocol previously described 
[50] 
using crosslinking chemistry with slight modifications. A solution of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride/N-hydroxysulfosuccinimide (EDC/NHS, Sigma-
Aldrich, USA) was prepared by adding 8 µL of EDC and 2 mg of NHS to 2 mL of 10 mM 2-(N-
morpholino)ethanesulfonic acid (MES, Sigma-Aldrich, USA). The pH was adjusted to 7.8. PEG (20 mg) 
was first added to the EDC/NHS solution and the AcDXSp nanoparticles (2 mg) were then suspended in 
the same solution, in an optimized ratio of 1:10 (AcDXSp:PEG), stirring at room temperature during 4 h 
in dark. AcDXSp-P nanoparticles were pelleted by centrifugation (16100g, 5 min) and the supernatant 
discarded. AcDXSp-P were resuspended in a solution of ANP in MES pH 8 (3.6 mg/mL) and kept under 
stirring during 3 h at room temperature, in dark. The resulting AcDXSp-P-ANP nanoparticles were 
washed twice with sucrose 2% (pH 8). For fluorescence labeling, AcDXSp were activated using 
EDC/NHS chemistry and AlexaFluor488® (500:1 AcDXSp:AF488, w/w) during 1 h. PEGylation and 
modification with ANP were performed, as described above. 
Physicochemical Characterization. The hydrodynamic diameter and polydispersity index (PdI) were 
measured in a disposable polystyrene cuvette (SARSTEDT AG & Co., Germany) by DLS, while ζ-
potential was measured in a disposable folded capillary cell (DTS1070, Malvern, UK) using a Zetasizer 
Nano ZS instrument (Malvern Instruments Ltd., UK). The surface chemical composition of the dry 
nanoparticles was evaluated by ATR–FTIR using a Bruker VERTEX 70 series FTIR spectrometer 





































































FTIR spectra were recorded in the wavenumber region of 4000–650 cm−1 with a resolution of 4 cm−1 at 
room temperature, using OPUS 5.5 software. The spectra were normalized between 0 and 1 for 
clarification. The amount of ANP covalently conjugated onto AcDXSp-PEG nanoparticles was 
determined by elemental analysis using a vario MICRO cube CHNS analyzer (Elementar 
AnalysenSystem) in dry samples. The percentages of carbon, hydrogen and nitrogen were recorded. The 
amount of ANP conjugated onto the nanoparticles’ surface was calculated based on the percentage of 
each element and the chemical structure of ANP. The nanoparticles’ morphology was evaluated by 
transmission electron microscopy (TEM, Jeol JEM-1400, Jeol Ltd., Japan). The samples were prepared 
by immersion of the carbon-coated copper grids (300 mesh; Electron Microscopy Sciences, USA) into a 
suspension of 0.1 mg/mL of the nanocarrier suspensions during approximately 1 min, blotted away and 
left to dry at room temperature overnight. To evaluate their dissolution behavior under different pH-
conditions, the AcDXSp nanoparticles, AcDXSp-P and AcDXSp-P-ANP were individually added into 
the buffer solution (pH 7.4 and 5.0) at a concentration of 1 mg/mL. Samples were taken at different time 
points (100 µL) to a TEA solution (0.01%, v/v; 1 mL, pH 8) to terminate the degradation process of 
AcDXSp, centrifuged (5 min, 16100g), and redispersed in TEA solution (0.01%, v/v; pH 8). The sample 
preparation for TEM imaging was similar to the described above. 
High-performance liquid chromatography (HPLC), determination of encapsulation efficiency (EE), 
loading degree (LD) and drug release tests. An Agilent 1100 series HPLC system (Agilent Technologies, 
Germany) was used to quantify the compounds encapsulated inside the nanoparticles. A Discovery® 5 
µm C18 reversed phase column (100  4.6 mm, Supelco, USA) was used. The mobile phase was 
Na2HPO4:citric acid (2:1) (pH 6.0) and acetonitrile (ACN) (50:50, v/v). The flow rate used was 1.4 
mL/min, the injection volume 5 μL, and the wavelength 274 ± 20 nm. For determination of EE (ratio 





































































of loaded drugs and total mass of drug-encapsulated nanoparticles), a known amount of CS@AcDXSp, 
CS@AcDXSp-P or CS@AcDXSp-P-ANP nanoparticles were dissolved in ACN. The CHIR99021 and 
SB431542 contents were measured by HPLC from the resulting solution, and all the supernatants 
resulting from the nanoparticle preparation. The in vitro release was assessed at pH-values of 7.4 and 
5.0, to simulate both the extracellular (pH 7.4) and intracellular (pH 5) microenvironments. The drug-
loaded nanoparticles were immersed in the appropriate release medium, stirring at 150 rpm and 37 ± 
1°C. Free CHIR99021 and SB431542 were used as controls. Samples of 200 mL were taken at specific 
time points and analyzed by HPLC, and the same volume of fresh preheated medium was replaced. 
Stability in Cell Medium. To evaluate the effect of the cell medium on nanoparticles’ hydrodynamic 
diameter and PdI, 600 µg of nanoparticles were dispersed into 200 μL of freshly prepared Milli-Q-water 
pH 8. The Z-average, PdI, and ζ -potential were measured for t = 0, and the nanoparticles were dispersed 
in 1 mL of complete Dulbecco’s Modified Eagle’s Medium (DMEM-F12) medium. Samples of 200 μL 
were diluted into 800 μL of Milli-Q water (pH 8) and measured at 10, 30, 60, 90 and 120 min. 
Isolation of Primary Cardiac Cells from Neonatal Rats. Primary cardiac cells were isolated as previously 
described.[51] Neonatal Wistar rats (1–4 days old) were sacrificed by decapitation, hearts taken, and atrial 
tissues were discarded. The ventricles were cut into small pieces and enzymatically digested by 
incubating at 37 °C with gentle mixing for 1:45 h in a collagenase/pancreatin (2 mg/mL). The cells in 
suspension were collected by centrifugation at 160g for 5 min. The supernatant and the top layer 
containing damaged cells were discarded, and the remaining cells were suspended in DMEM/F12 
(Gibco) supplemented with 2.5 mM L-glutamine, 1% of penicillin-streptomycin (PS, HyCloneTM) and 
10% fetal bovine serum (FBS, HyCloneTM). The cells were pre-plated for about 1:20h to separate 
cardiomyocytes from non-myocytes,[52] whereafter the unattached cardiomyocytes were plated at a 
desired density for experiments. After 24 h, the cardiomyocyte medium was replaced with complete 





































































insulin, 2.5 mM L-glutamine, 32 nM selenium, 2.8 mM sodium pyruvate, 5.64 μg/mL transferrin, 1 nM 
T3, and 1% PS). Non-myocytes were cultured in complete DMEM/F12 until confluent and plated for the 
experiments. On the following day, the medium was changed to serum-free DMEM + 1% PS, 18 h prior 
to experiments, and these conditions were maintained during the experiments. The cells were maintained 
at 37 °C with 5% CO2 and 95% air in a humidified atmosphere.  
Cell Viability Studies. The cellular viability of non-myocytes was evaluated using a luminescence assay. 
Cardiac non-myocytes were seeded at densities of 1×104 cells/well in 96-well plates (Corning, USA), 
and allowed to attach overnight. Nanoparticle suspensions were prepared at different concentrations (10, 
25, 50, 100, and 250 μg/mL) in DMEM-F12. After incubation at 37 °C for 6 h, the plates were brought 
to room temperature for 30 min and washed twice with Hank's Balanced Salt Solution (N-[2-
hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]) (HBSS−HEPES, pH 7.4). The assay reagent 
(CellTiter-Glo®, Promega, USA) was added to each well, the plates were shaken for 2 min, and the 
luminescence was measured using a Varioskan Flash Multimode Reader (Thermo Fisher Scientific). For 
cardiomyocytes, the cell viability was measured taking into account the ability to metabolize 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).[53] MTT (Sigma-Aldrich, USA) was 
prepared in HBSS−HEPES pH 7.4 (2.5 mg/mL), sterile-filtered with a 0.2 µM syringe filter (Millipore) 
and stored at +4°C for further use. After a 6-h exposure to nanoparticles, MTT was added to the cells at 
0.5 mg/mL and incubated for 2.5 h at +37°C. The supernatant was then carefully removed and 100 µL 
of DMSO were added. The absorbance was measured using a Varioskan Flash Multimode Reader 
(Thermo Fisher Scientific) at 490 nm. Negative (1% Triton X-100), positive (cell medium) and blank 
(only Cell-titer reagent or MTT solution) controls were used and treated similarly. 
Cell-nanoparticle Interactions. Non-myocytes seeded at a density of 105 cells/well were incubated with 
Alexafluor 488-labeled nanoparticles (25 μg/mL) for 1 h. A pre-treatment with ANP (100 µM) was 





































































duration of the nanoparticle exposure. The cells were then washed three times and collected with 
trypsinization. The measurements were performed using an LSRII flow cytometer (BD Biosciences, 
USA) with a laser excitation wavelength of 488 nm. To analyze the internalization of nanoparticles, the 
fluorescence of membrane-associated nanoparticles was quenched by incubating the cells in trypan blue 
(0.005% v/v). Approximately 10000 events were obtained per sample. The data analysis was performed 
using FlowJo X 10.0.7r2 software. 
Immunostainings and High Content Cell Imaging. Non-myocytes were seeded at a density of 104 
cells/well in 96-well plates. The nanoparticle suspensions or free drugs were added to each well at 
concentrations of 1 µM for CHIR99021 and 2.1 µM for SB431542, and incubated for 6 h. Cells were 
washed twice with PBS and fixed with 4% paraformaldehyde for 20 min. After 35 min washes with 
PBS, cells were permeabilized with 0.1% Triton X-100 for 10 min, washed 3 times with PBS and blocked 
with 4% FBS in PBS for 45–60 min. Cells then were incubated with primary antibodies (β-catenin (1:200, 
ab32572, Abcam), Smad3 (1:250, sc-101154, Santa cruz), α-SMA (1:250, A-2547, Sigma) and vimentin 
(1:200, D21H3, Cell Signaling)) for 60 min at room temperature, shaking at 300 rpm, followed by 35 
min washes with PBS. Secondary antibodies were added to each well (anti-mouse 488 (1:250, A11029), 
anti-mouse 647 (1:250, A21236), anti-rabbit 488 (1:200, A11034), anti-rabbit 647 (A31573) (all from 
Invitrogen, USA) and DAPI, (1:250, Vector Laboratories) and incubated for 45 min at room temperature, 
shaking at 300 rpm. Cells were washed 3 5 min with PBS and stored at +4°C until imaging. The images 
captured using a Cellomics CellInsight high-content analysis platform (Thermo Scientific) with a 10x 
objective and analyzed simultaneously using a protocol based on Compartmental Analysis 
bioapplication. DAPI staining was used to define the nuclei and a 5-pixel ring around the nuclear mask 





































































Statistical Analysis. Statistical analyses were performed using one-way ANOVA with Tukey-Kramer 
post hoc test or Student’s t-test. The levels of significance were set at probabilities of *, #, §, ᴥp < 0.05, **, 
##p < 0.01, and ***, §§§p < 0.001. 
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Pharmacological cellular reprogramming is a highly relevant therapeutic strategy towards cardiac 
regeneration, and the application of nanoparticles in this emerging field has been scarcely 
explored. Here, a dual-loaded multifunctional and cardiac-specific nanoparticulate system for potential 
application in cellular reprogramming of non-myocytes into cardiomyocyte-like cells is reported, 
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